Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00189202 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00189202 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 49 participants.
The verdict
NCT00189202, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
African Americans receiving a kidney transplant are considered at high risk for early rejection of their transplanted kidney and require more immunosuppression to maintain their kidney transplant function. This increase in immunosuppression puts this group at risk for drug-related toxicities and complications such as post-transplant diabetes. This study will evaluate: 1. Whether a sirolimus based steroid avoidance regimen in African Americans may decrease the risks of drug-related toxicities, 2. Decreased rates of metabolic complications such as post-transplant diabetes, 3. The effect of Sirolimus plus a reduced dose cyclosporine on renal allograft function.
Interventions
- DRUG Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2004-08 |
| Est. Completion | 2008-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00189202
The ClinicalTrials.gov registry entry for NCT00189202 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.
NCT00189202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00189202 about?
NCT00189202 is a clinical study titled "Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans". African Americans receiving a kidney transplant are considered at high risk for early rejection of their transplanted kidney and require more immunosuppression to maintain their kidney transplant function. This increase in immunosuppression puts this group at risk for drug-related toxicities and com...
What is the current status of trial NCT00189202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2004-08. Estimated completion is 2008-07-01.
What interventions are being tested in trial NCT00189202?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT00189202?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.